Skip to main content
Equibles
EQ logo

EQ · Equillium, Inc.

Track EQ — free

Use EQ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EQ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.11 -0.31 (-12.81%) At close · Sep 11
Rebalance outlook locked
Market Cap
$133.79M
Shares
63.41M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.11 Open$2.46 Day$2.11–2.46 52W close$0.84–3.20 Avg vol 30d472K Short int5.4M · 8.5% float · 13.1d Short vol59% Last earningsMay 27, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Apr 1, 2027 Est · unconfirmed · in 29 wks
Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$41.09M
Trailing 12 months
Net income (TTM)
−$18.01M
Trailing 12 months
Revenue growth YoY
-52.3%
Year over year
Operating margin
-20.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-15.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+213.0%
Year over year · more shares
Price change (1Y)
+6.0%
Trailing year
Short interest
8.5%
Latest settlement · 13.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +5%
above
Price vs 50-day avg −13%
below
RSI (14) 42
neutral
MACD trend Positive
52-week position 54%
mid-range
Momentum
relative strength
Strong
1-month return +5%
trailing
6-month return −1%
trailing
YTD return +36%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+20% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.47% of float · ▼ -3.0% MoM · 13.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
60 holders — near 3-yr high, broad support
Squeeze score 60
elevated · 0–100
Fundamentals
Fair
Revenue growth +14%
Y/Y
EPS growth −70%
Y/Y
Free cash flow $-22.8M
Balance sheet $50.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 106%
annualized · 1-yr
Max drawdown −58%
past year
ATR 9.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+5% Bullish
Price vs 50-day avg
−13% Bearish
RSI (14)
42 Neutral
MACD trend
Positive Bullish
52-week position
54% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+20% holders QoQ · +19 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.47% of float · ▼ -3.0% MoM · 13.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
60 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $2 · 54% Range high $3
vs 200-day avg +5% vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EQ
Equillium, Inc.
this stock
$133.79M +36.1% +13.9% — 8.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
60
% held
66.1%
Net QoQ
+1.2M sh
Top holder
Jupiter Topco LLC
Held Float
View
Held by Funds
Fund positions
15
View
Short & Settlement
Short Interest Falling
Shares short
5.4M
Days to cover
13.1d
Change
-163.8K sh
View
Short Volume
Short vol %
59%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
2.0K
Value
$4.5K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
43.8%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$41.1M
Net income (FY)
$-22.4M
EPS diluted
$-0.39
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
9
View
Proposed Sales
Value
$91.1K
Shares
31.0K
Filed
Jun 5, 2026
View
Earnings & Events
Earnings Calls
Last call
May 27, 2026
View
Investor Relations
Latest news
Equillium to Participate in Upcom…
Published
Sep 2, 2026
View

Performance

5D 20D 120D MTD YTD
EQ -5.0% +5.0% -0.9% -7.1% +36.1%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -3.8% +6.7% -18.8% -6.7% +24.1%
Key facts CIK 1746466 CUSIP 29446K106 13F (30d) 32 filings 32 filers Visit website Investor relations